MedicarePartD.guide

A non-government resource built from CMS public data

TNF blockers on every 2026 Kansas Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in Kansas cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days

12 plans, cheapest premium first. Scroll sideways for all of them →

TNF blockers by 2026 Kansas Part D plan
DrugBlue MedicareRx Essentials$0.00/moS5726-020Blue MedicareRx Value$0.70/moS5726-013HealthSpring Assurance Rx$6.70/moS5617-118Wellcare Value Script$9.60/moS4802-157Wellcare Classic$14.70/moS4802-088Humana Basic Rx Plan$15.50/moS5884-109Humana Value Rx Plan$55.60/moS5884-203Blue MedicareRx Plus$67.40/moS5726-014SilverScript Choice$88.30/moS5601-048AARP Medicare Rx Saver from UHC$105.40/moS5921-369Humana Premier Rx Plan$116.30/moS5884-170AARP Medicare Rx Preferred from UHC$147.00/moS5921-405
HumiraadalimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 52/365dNot coveredNot coveredNot covered
adalimumab biosimilarsadalimumab-adaz, -fkjp, -aacf and othersNot coveredNot coveredNot coveredTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dTier 5PA25%QL 0.2/28dTier 5PA26%QL 0.2/28dNot coveredNot coveredTier 5PA25%Tier 5PA33%QL 0.2/28dTier 5PA31%
Hadlimaadalimumab-bwwdTier 5PA25%QL 2.4/28dTier 5PA25%QL 2.4/28dTier 5PA25%QL 2.4/28dNot coveredNot coveredNot coveredNot coveredTier 5PA33%QL 2.4/28dTier 5PA25%QL 22.4/365dNot coveredNot coveredNot covered
Hyrimozadalimumab-adazNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Cyltezoadalimumab-adbmNot coveredNot coveredNot coveredTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Simlandiadalimumab-ryvkTier 5PA25%QL 3/28dTier 5PA25%QL 3/28dNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA33%QL 3/28dNot coveredNot coveredNot coveredNot covered
Yuflymaadalimumab-aatyNot coveredNot coveredNot coveredTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Amjevitaadalimumab-attoNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
EnbreletanerceptTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA26%QL 8/28dTier 5PA33%QL 2/28dTier 5PA25%QL 8/28dTier 5PA25%QL 4/28dTier 5PA33%QL 8/28dTier 5PA31%QL 4/28d
Cimziacertolizumab pegolNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
SimponigolimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.